> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AnazaoHealth FDA-483
- URL: https://www.fdaweb.com/anazaohealth-fda-483/
- Published: 2019-12-03T12:00:00.000Z
- Updated: 2026-09-14T15:55:11.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145638

FDA has released the FDA-483 issued following a 9/9-9/19 inspection at AnazaoHealth, a Las Vegas, NV, outsourcing facility. The three inspection observations [were](https://www.fda.gov/media/132898/download?ref=fdaweb.com): 

- aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions;
- the flow of components, drug product containers, and in-process materials through the building is not designed to prevent contamination; and
- bulk drug substances used by the outsourcing facility to compound drug products are not each manufactured by an establishment registered under section 510 of the Federal Food, Drug, and Cosmetic Act.